Table 4 Safety profile of omalizumab-assisted oral immunotherapy
From: Omalizumab in children with severe allergic disease: a case series
Patient | Symptoms | Concomitant Trigger | Milk (mL) | OIT step | Emergency treatment | Outcome |
|---|---|---|---|---|---|---|
3 | Rhinitis | No | 120 | 18th week (OIT) | Antihistamine | Failed |
Rhinitis and asthma | Acute illness | 100 | 20th week (OIT) | Antihistamine and Salbutamol | ||
Anaphylaxis | Acute illness | 140 | 22th week (OIT) | Adrenaline OIT discontinued | ||
5 | No | NA | NA | NA | NA | Desensitization |
6 | Urticaria and sickness | No | 18 | 12th week (O + OIT) | Antihistamine Corticosteroids | Failed |
Urticaria | No | 7 | 15th week (O + OIT) | Antihistamine | ||
Urticaria | No | 4 | 20th week (O + OIT) | Antihistamine | ||
Anaphylaxis | No | 10 | 52th week (OIT) | Adrenaline OIT discontinued | ||
7 | No | NA | NA | NA | NA | Desensitization |
8 | Anaphylaxis | Acute illness | 150 | 52th week (OIT) | Adrenaline OIT discontinued | Failed |